GlobeNewswire Inc.··NaaTyr Pharma Advances Sarcoidosis Drug After FDA Meeting, Extends Cash Runway
aTyr Pharma advances efzofitimod into Phase 3 pulmonary sarcoidosis development following FDA meeting, maintains $68.3M cash position.
ATYRclinical developmentinterstitial lung disease